Panobinostat - CAS 404950-80-7
Catalog number: B0084-141578
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C21H23N3O2
Molecular Weight:
349.434
COA:
Inquire
Targets:
HDAC
Description:
Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-141578 500 mg $298 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
Light yellow to yellow Solid
Synonyms:
LBH-589; NVP-LBH-589
MSDS:
Inquire
InChIKey:
FPOHNWQLNRZRFC-ZHACJKMWSA-N
InChI:
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
Canonical SMILES:
CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO
Current Developer:
Novartis Oncology.
1.Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K1, Beggs AE2, Campbell H2, Kodali L2, Ford PD3. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487.
PURPOSE: The mechanism of action, pharmacodynamics, pharmacokinetics, clinical efficacy, interaction potential, adverse effects, and place in therapy of panobinostat are reviewed.
2.Dinutuximab and Panobinostat.
Chasick A1, Solimando DA Jr1, Waddell JA1. Hosp Pharm. 2015 Oct;50(9):767-72. doi: 10.1310/hpj5009-767. Epub 2015 Oct 14.
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.
3.Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine.
Gupta S1, Chaudhary K1, Kumar R1, Gautam A1, Nanda JS1, Dhanda SK1, Brahmachari SK2, Raghava GP1. Sci Rep. 2016 Mar 31;6:23857. doi: 10.1038/srep23857.
In this study, we investigated drug profile of 24 anticancer drugs tested against a large number of cell lines in order to understand the relation between drug resistance and altered genomic features of a cancer cell line. We detected frequent mutations, high expression and high copy number variations of certain genes in both drug resistant cell lines and sensitive cell lines. It was observed that a few drugs, like Panobinostat, are effective against almost all types of cell lines, whereas certain drugs are effective against only a limited type of cell lines. Tissue-specific preference of drugs was also seen where a drug is more effective against cell lines belonging to a specific tissue. Genomic features based models have been developed for each anticancer drug and achieved average correlation between predicted and actual growth inhibition of cell lines in the range of 0.43 to 0.78. We hope, our study will throw light in the field of personalized medicine, particularly in designing patient-specific anticancer drugs.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HDAC Products


CAS 1622921-15-6 Remodelin

Remodelin
(CAS: 1622921-15-6)

Remodelin, via inhibition of NAT10, mediates nuclear shape rescue of LMNA depleted cells by microtubule reorganization, and improves nuclear shape and fitness o...

CAS 128517-07-7 Romidepsin

Romidepsin
(CAS: 128517-07-7)

Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM ...

CAS 1252003-15-8 Tubastatin A

Tubastatin A
(CAS: 1252003-15-8)

Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately...

CAS 112522-64-2 Tacedinaline

Tacedinaline
(CAS: 112522-64-2)

Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits his...

CAS 1186222-89-8 4SC-202

4SC-202
(CAS: 1186222-89-8)

4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic act...

CAS 404950-80-7 Panobinostat

Panobinostat
(CAS: 404950-80-7)

Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), induci...

ACY-738
(CAS: 1375465-91-0)

ACY-738 is a potent and selective HDAC6 inhibitor with improved brain bioavailability. ACY-738 inhibits HDAC6 with low nanomolar potency and a selectivity of 60...

CAS 410536-97-9 Sirtinol

Sirtinol
(CAS: 410536-97-9)

Sirtinol is a SIRT inhibitor. Sirtinol significantly increased the acetylation of p53, which has been reported to be a target of SIRT1/2. Sirtinol significantly...

CAS 910462-43-0 4SC-202

4SC-202
(CAS: 910462-43-0)

4SC-202 is a selective and potent, orallly available inhibitor of histone deacetylases (HDAC) specific for class 1 HDAC isoenzymes, with IC50 of 1.20 μM, 1.12 μ...

CAS 1310693-92-5 Tubastatin A HCl salt

Tubastatin A HCl salt
(CAS: 1310693-92-5)

Tubastatin A is a potent and selective HDAC6 inhibitor. Tubastatin A was substantially more selective than the known HDAC6 inhibitor Tubacin at all isozymes exc...

CAS 1688677-89-5 LW479

LW479
(CAS: 1688677-89-5)

LW479 is a HDAC inhibitor with marked cytotoxicity leading to apoptosis and cell cycle arrest in a panel of breast cancer cell lines. LW479 silences EGFR expres...

CAS 875320-29-9 Quisinostat

Quisinostat
(CAS: 875320-29-9)

Quisinostat, also known as JNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potent...

CAS 1314890-29-3 TMP269

TMP269
(CAS: 1314890-29-3)

TMP269 is a highly potent, selective and cell-permeable class IIa HDAC inhibitor with IC50 values of 126 nM, 80 nM, 36 nM and 19 nM for HDAC4, HDAC5, HDAC7 and ...

CAS 99873-43-5 Droxinostat

Droxinostat
(CAS: 99873-43-5)

Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respec...

CAS 414864-00-9 Belinostat

Belinostat
(CAS: 414864-00-9)

Belinostat is a hydroxamic acid-type histone deacetylase (HDAC) inhibitor. Belinostat targets HDAC enzymes to inhibit tumor cell proliferation and angiogenesis,...

CAS 404951-53-7 Dacinostat

Dacinostat
(CAS: 404951-53-7)

Dacinostat, also known as LAQ824, is a hydroxamate histone deacetylase inhibitor with potential anticancer activity. LAQ824 sensitized nonsmall cell lung cancer...

CAS 99-66-1 Valproic acid

Valproic acid
(CAS: 99-66-1)

Valproic acid is an inhibitor of histone deacetylase (HDAC) inhibitor, which has an anticancer effect. It is a branched short-chain fatty acid. It is previously...

CAS 20554-84-1 (-)-Parthenolide

(-)-Parthenolide
(CAS: 20554-84-1)

(-)-Parthenolide is a sesquiterpene lactone which occurs naturally in the plant feverfew(Tanacetum parthenium) and also promotes the ubiquitination of MDM2 and ...

BG45
(CAS: 926259-99-6)

BG45 is a class I HDAC inhibitor with IC50 of 289 nM, 2.0 µM, 2.2 µM and >20 µM for HDAC3, HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively.

CAS 1012054-59-9 CUDC-101

CUDC-101
(CAS: 1012054-59-9)

CUDC-101 is a multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human e...

Chemical Structure

CAS 404950-80-7 Panobinostat

Quick Inquiry

Verification code

Featured Items